Results 191 to 200 of about 1,104,154 (232)
A call for action: Closing the evidence gap in management of stimulant‐induced psychosis
Addiction, Volume 121, Issue 9, Page 2275-2283, September 2026.Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier +3 more
wiley +1 more source
Staff Perspectives on Interventions for Confabulation in Brain Injury and Dementia
Australasian Journal on Ageing, Volume 45, Issue 3, September 2026.ABSTRACT Objective Providing inaccurate narratives of events (confabulation) is a commonly reported difficulty for people with brain injuries and dementia. We aimed to capture staff perceptions on the frequency and cause of confabulation, as well as interventions they find acceptable and effective. Methods We surveyed staff in dementia and brain injury
Rebecca Sharp +2 more
wiley +1 more source
The Vicissitudes of the Nafs: Madness, Paralysis, and the Work of Transgression in Sufi Ethics
Anthropology of Consciousness, Volume 37, Issue 2, Fall 2026.ABSTRACT How should we theorize Sufi ethics when the practice of zikr (remembrance) that leads to spiritual enlightenment (tazkiyya) might also bring one to the brink of majzubiyat (madness)? What forms of regulation or restraint are imagined or enacted by practitioners to prevent spiritual boundlessness from perverting into its underside of paralysis (
Muhammad Osama Imran
wiley +1 more source
A Somatic-Type Delusional Disorder Resulted in Severe Weight Loss With a Body Mass Index of 10.2: A Case Report. [PDF]
CureusIbn Auf A, Bedeer EM, Almarzoogi AM.
europepmc +1 more source
Xanomeline and Trospium Chloride: Mechanism of Action, Clinical, and Translational Science
Clinical and Translational Science, Volume 19, Issue 9, September 2026.ABSTRACT Xanomeline‐trospium chloride (Cobenfy, formerly KarXT) is a first‐in‐class, oral central M1/M4 muscarinic receptor agonist approved for the treatment of schizophrenia in adults. Cobenfy represents a paradigm shift by avoiding direct dopamine D2 receptor blockade and thus significantly reduces the burden of metabolic, extrapyramidal, and ...
Samantha Avila, Ingrid L. Chen
wiley +1 more source
European Journal of Neuroscience, Volume 64, Issue 5, September 2026.We recorded fMRI data during the N‐back task from 38 individuals with schizophrenia and 128 healthy participants and used moderated mediation analysis to examine the interactions between childhood trauma, frontoparietal connectivity and working memory performance.
Aoife Warren +7 more
wiley +1 more source